Literature DB >> 9525672

Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.

X F Yu1, L Dawson, C J Tian, C Flexner, M Dettenhofer.   

Abstract

One of the crucial steps in the assembly of the human immunodeficiency virus type 1 (HIV-1) and other retroviruses is the incorporation and retention of all the key viral enzymes in released virions. The viral enzymes protease, reverse transcriptase, and integrase of HIV-1 are initially synthesized as Gag-Pol fusion polyproteins. It has been shown that the incorporation of Gag-Pol polyproteins during virus assembly requires the Gag domains that are shared by the Gag and Gag-Pol precursors. We now report that truncation of the C-terminal p6 domain of HIV-1 Gag, which is present in the Gag precursor but not in the Gag-Pol precursor, drastically reduced the amount of Pol proteins in the mutant virions. Mutations in the lentivirus conserved motif P(T/S)APP in p6 also drastically reduced the amount of Pol proteins in mutant virions. The steady-state levels of Gag-Pol precursors and cleaved Pol proteins in the transfected cells were not affected by mutations in p6. The incorporation of unprocessed Gag-Pol precursors into p6 mutant virions was detected when the viral protease was mutated, suggesting that the interactions among mutant Gag molecules and Gag-Pol precursors were not significantly affected. These results suggest that the p6 domain of HIV-1 Gag may play an important role in recruiting or retaining cleaved Pol proteins during virus assembly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525672      PMCID: PMC109837     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Point mutations in the P30 domain of the gag gene of Moloney murine leukemia virus.

Authors:  H W Hsu; P Schwartzberg; S P Goff
Journal:  Virology       Date:  1985-04-15       Impact factor: 3.616

Review 2.  Proteolytic processing and particle maturation.

Authors:  V M Vogt
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

3.  HIV-1 particle release mediated by Vpu is distinct from that mediated by p6.

Authors:  M D Schwartz; R J Geraghty; A T Panganiban
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

4.  Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1.

Authors:  J Mak; A Khorchid; Q Cao; Y Huang; I Lowy; M A Parniak; V R Prasad; M A Wainberg; L Kleiman
Journal:  J Mol Biol       Date:  1997-01-31       Impact factor: 5.469

5.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

6.  Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation.

Authors:  R Schneider; M Campbell; G Nasioulas; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein.

Authors:  M Huang; M A Martin
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Mutations in the gag gene of Moloney murine leukemia virus: effects on production of virions and reverse transcriptase.

Authors:  P Schwartzberg; J Colicelli; M L Gordon; S P Goff
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

10.  The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle.

Authors:  X Yu; Q C Yu; T H Lee; M Essex
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more
  25 in total

Review 1.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 2.  Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Authors:  Gilles Mirambeau; Sébastien Lyonnais; Robert J Gorelick
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

3.  Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.

Authors:  M A Accola; B Strack; H G Göttlinger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Authors:  Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

5.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 6.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

7.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.

Authors:  C Chen; F Li; R C Montelaro
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Authors:  S Peters; M Muñoz; S Yerly; V Sanchez-Merino; C Lopez-Galindez; L Perrin; B Larder; D Cmarko; S Fakan; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

10.  Functional complementation of nucleocapsid and late domain PTAP mutants of human immunodeficiency virus type 1 during replication.

Authors:  Olga A Nikolaitchik; Robert J Gorelick; Maria G Leavitt; Vinay K Pathak; Wei-Shau Hu
Journal:  Virology       Date:  2008-03-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.